15 studies found for:    elotuzumab AND myeloma
Show Display Options
Rank Status Study
1 Active, not recruiting A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
Condition: Hematologic Cancer
Interventions: Biological: elotuzumab (HuLuc63);   Drug: lenalidomide;   Drug: dexamethasone
2 Active, not recruiting Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Condition: Smoldering Multiple Myeloma
Intervention: Biological: Elotuzumab (BMS-901608; HuLuc63)
3 Recruiting S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Myeloma
Interventions: Biological: elotuzumab;   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
4 Active, not recruiting Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab;   Drug: Bortezomib;   Drug: Dexamethasone
5 Active, not recruiting Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63)
6 Not yet recruiting A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lirilumab;   Drug: Urelumab
7 Active, not recruiting Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition: Relapsed and/or Refractory Multiple Myeloma
Interventions: Biological: Elotuzumab;   Biological: Thalidomide;   Biological: Dexamethasone;   Biological: Cyclophosphamide
8 Active, not recruiting Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Conditions: Lymphoma (Myeloma);   Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone (Oral);   Drug: Dexamethasone (IV);   Biological: Elotuzumab (BMS-901608; HuLuc63)
9 Completed Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: HuLuc63
10 Terminated A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.
Condition: Multiple Myeloma
Intervention: Drug: Elotuzumab (HuLuc63)
11 Recruiting Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lenalidomide;   Drug: Dexamethasone
12 Active, not recruiting Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63)
13 Active, not recruiting PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
Condition: Newly Diagnosed, Previously Untreated Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Biological: Elotuzumab
14 Not yet recruiting Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608)
15 Active, not recruiting Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone
Condition: Multiple Myeloma
Intervention: Biological: BMS-901608 (Elotuzumab)

Indicates status has not been verified in more than two years